Immunovant (IMVT)
(Delayed Data from NSDQ)
$15.71 USD
-0.37 (-2.30%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $15.46 -0.25 (-1.59%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Immunovant, Inc. has a market cap of $2.75B, which represents its share price of $16.08 multiplied by its outstanding shares number of 171.07M. As a mid-cap company, IMVT's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
IMVT 15.71 -0.37(-2.30%)
Will IMVT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMVT
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy
Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?
IMVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Other News for IMVT
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Immunovant (IMVT) Price Target Raised to $18 by UBS Analyst
Immunovant price target raised by $1 at UBS, here's why
UBS Raises Price Target for Immunovant (IMVT) to $18.00 | IMVT Stock News
IMVT Stock Offering Managed by Morgan Stanley Sees Wide Price Range | IMVT Stock News